<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04875026</url>
  </required_header>
  <id_info>
    <org_study_id>W00118 CR 401</org_study_id>
    <secondary_id>2020-000851-11</secondary_id>
    <nct_id>NCT04875026</nct_id>
  </id_info>
  <brief_title>Frequency and Intensity of Local Reactions in Patients Treated With 4% 5-FU vs 4% 5-FU Associated With an Emollient Cream: a Randomised, Controlled Clinical Trial</brief_title>
  <acronym>TOLAK</acronym>
  <official_title>Frequency and Intensity of Local Reactions in Patients Treated With 4% 5-FU vs 4% 5-FU Associated With an Emollient Cream: a Randomised, Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinact</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pierre Fabre Medicament</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transient local skin reactions with topical Actinic Keratosis treatments such as&#xD;
      5-FluoroUracil (5-FU) often lead to non-adhesion from patients and thus to treatment failure.&#xD;
      In regards to 5-FU treatment, these local reactions are related to the pharmacological action&#xD;
      of the molecule. The current therapeutic challenge is to reduce the local reactions induced&#xD;
      by 5-FU without interfering with its efficacy, in particular by the use of an emollient&#xD;
      cream.&#xD;
&#xD;
      The aim of the present study is to investigate how the use of an emollient, namely Dexeryl,&#xD;
      could improve the local skin reactions occurring during 4 weeks of a 4% 5-FU treatment&#xD;
      (Tolak).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 16, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>This study is investigator-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Local Skin Reaction (LSR) total score</measure>
    <time_frame>at 4 weeks or Last Observation Carried Forward (LOCF)</time_frame>
    <description>Investigator-assessed score: 6 objective items scored from 0-4 (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, erosion/ulceration) for a minimal score of 0 (best outcome possible), and a maximal score of 24 (worst outcome possible).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local Skin Reaction (LSR) total score</measure>
    <time_frame>at 2 weeks (first follow-up)</time_frame>
    <description>Investigator-assessed score: 6 objective items scored from 0-4 (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, erosion/ulceration) for a minimal score of 0 (best outcome possible), and a maximal score of 24 (worst outcome possible).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Skin Reaction (LSR) total score</measure>
    <time_frame>at 8 weeks (last follow up)</time_frame>
    <description>Investigator-assessed score: 6 objective items scored from 0-4 (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, erosion/ulceration) for a minimal score of 0 (best outcome possible), and a maximal score of 24 (worst outcome possible).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Skin Reaction (LSR) items alone</measure>
    <time_frame>at 2 weeks (first follow-up)</time_frame>
    <description>Presence/absence/intensity of each item of the LSR: 6 objective items scored from 0-4 (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, erosion/ulceration). For each item, 0 is the best outcome possible, 4 is the worst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Skin Reaction (LSR) items alone</measure>
    <time_frame>at 4 weeks (second follow up)</time_frame>
    <description>Presence/absence/intensity of each item of the LSR: 6 objective items scored from 0-4 (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, erosion/ulceration). For each item, 0 is the best outcome possible, 4 is the worst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Skin Reaction (LSR) items alone</measure>
    <time_frame>at 8 weeks (last follow up)</time_frame>
    <description>Presence/absence/intensity of each item of the LSR: 6 objective items scored from 0-4 (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, erosion/ulceration). For each item, 0 is the best outcome possible, 4 is the worst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective signs at each visit</measure>
    <time_frame>at 2 weeks (first follow-up)</time_frame>
    <description>Patient questionnaire evaluating prurit (0-3), stinging/burning (0-3), pain (0-4). 0 is the best outcome, 10 is the worst outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective signs at each visit</measure>
    <time_frame>at 4 weeks (second follow up)</time_frame>
    <description>Patient questionnaire evaluating prurit (0-3), stinging/burning (0-3), pain (0-4). 0 is the best outcome, 10 is the worst outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective signs at each visit</measure>
    <time_frame>at 8 weeks (last follow up)</time_frame>
    <description>Patient questionnaire evaluating prurit (0-3), stinging/burning (0-3), pain (0-4). 0 is the best outcome, 10 is the worst outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local reactions according to Common Terminology Criteria for Adverse Event (CTCAE) grade 3 or 4</measure>
    <time_frame>at 2 weeks (first follow-up)</time_frame>
    <description>Intensity grading of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local reactions according to Common Terminology Criteria for Adverse Event (CTCAE) grade 3 or 4</measure>
    <time_frame>at 4 weeks (second follow up)</time_frame>
    <description>Intensity grading of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local reactions according to Common Terminology Criteria for Adverse Event (CTCAE) grade 3 or 4</measure>
    <time_frame>at 8 weeks (last follow up)</time_frame>
    <description>Intensity grading of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events reported by patients or noticed by investigator</measure>
    <time_frame>at 2, 4 and 8 weeks (first follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drop outs due to Adverse Events (AE) related to local skin reaction</measure>
    <time_frame>at 2, 4 and 8 weeks (first follow-up)</time_frame>
    <description>discontinuation rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue treatment</measure>
    <time_frame>at 2 weeks (first follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue treatment</measure>
    <time_frame>at 4 weeks (second follow up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue treatment</measure>
    <time_frame>at 8 weeks (last follow up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction (acceptability): measured by Treatment Satisfaction Questionnaire for Medication version 9 (TSQM-9)</measure>
    <time_frame>at 4 weeks (end of treatment) or at Patient Withdrawal</time_frame>
    <description>The TSQM-9 questionnaire includes nine questions that assess patients' satisfaction by providing score on three scales: effectiveness (questions 1 to 3), convenience (questions 4 to 6) and global satisfaction (questions 7 to 9). The scores of each scale range from 0 to 100, where a higher score indicates a greater satisfaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment adherence</measure>
    <time_frame>at 4 weeks</time_frame>
    <description>assessed by the participant using a self questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment adherence</measure>
    <time_frame>at optional visit (when applicable), up to 8 weeks</time_frame>
    <description>assessed by the participant using a self questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life measured by actinic keratosis quality of life questionnaire (AKQoL)</measure>
    <time_frame>at 8 weeks (last follow up)</time_frame>
    <description>actinic keratosis quality of life patient questionnaire, for Spain and Germany only. 0 is the best outcome, 27 is the worst outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of patients with complete and partial clearance rates</measure>
    <time_frame>at 8 weeks (last follow up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of patients with partial clearance rates</measure>
    <time_frame>at 8 weeks (last follow up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in number of AK lesions</measure>
    <time_frame>at baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in number of AK lesions</measure>
    <time_frame>at 2 weeks (first follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of AK lesions</measure>
    <time_frame>at 2 weeks (first follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in number of AK lesions</measure>
    <time_frame>at 4 weeks (second follow up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of AK lesions</measure>
    <time_frame>at 4 weeks (second follow up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in number of AK lesions</measure>
    <time_frame>at 8 weeks (last follow up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of AK lesions</measure>
    <time_frame>at 8 weeks (last follow up)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Actinic Keratoses</condition>
  <arm_group>
    <arm_group_label>5-fluorouracil 4% (Tolak) + Dexeryl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will apply 5-FU once daily for 4 weeks, and Dexeryl once daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-fluorouracil 4% (Tolak)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This group will only apply 5-FU once daily for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil 4% (Tolak)</intervention_name>
    <description>Application of Tolak once daily in the evening for 4 weeks</description>
    <arm_group_label>5-fluorouracil 4% (Tolak)</arm_group_label>
    <arm_group_label>5-fluorouracil 4% (Tolak) + Dexeryl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dexeryl</intervention_name>
    <description>Application of Dexeryl once daily in the morning for 8 weeks</description>
    <arm_group_label>5-fluorouracil 4% (Tolak) + Dexeryl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants are eligible only if all of the following criteria apply:&#xD;
&#xD;
        Age&#xD;
&#xD;
          1. Participant must be more than 18 years old inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
             Type of Participant and Disease Characteristics&#xD;
&#xD;
          2. Individuals with a clinical diagnosis of actinic keratosis (AK).&#xD;
&#xD;
          3. Individuals harboring 5 or more clinically recognizable (palpable and/or visible to&#xD;
             unaided eye) AK lesions of the face, and/or ears and/or scalp. The AK lesions must be&#xD;
             clinically typical non hypertrophic and/or nonhyperkeratotic.&#xD;
&#xD;
          4. Subject in good general condition and free of any disease state or condition which, in&#xD;
             the investigator's opinion, could impair evaluation of actinic keratosis or could&#xD;
             expose the subject to an unacceptable risk by study participation.&#xD;
&#xD;
             Sex&#xD;
&#xD;
          5. Male or female. A Female participant is eligible to participate if she is not a woman&#xD;
             of childbearing potential (WOCBP), defined as postmenopausal (cessation of menses &gt;12&#xD;
             months) or surgically sterile (history of bilateral tubal ligation, bilateral&#xD;
             oophorectomy, total hysterectomy).&#xD;
&#xD;
             Informed Consent&#xD;
&#xD;
          6. Capable of giving signed informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the informed consent form (ICF) and in this&#xD;
             protocol.&#xD;
&#xD;
             Ethical/Legal considerations&#xD;
&#xD;
          7. Affiliated to a social security system, or is a beneficiary (if applicable in the&#xD;
             national regulation).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants are excluded from the study if any of the following criteria apply:&#xD;
&#xD;
        Medical Conditions&#xD;
&#xD;
          1. With AK lesions within treatment areas which are hyperkeratotic or which are&#xD;
             clinically suspected to be squamous cell carcinoma (SCC).&#xD;
&#xD;
          2. With pre-existing local skin reactions with a total score ≥ 3.&#xD;
&#xD;
          3. History of hypersensitivity to the ingredients of Tolak® or Dexeryl®.&#xD;
&#xD;
          4. With a known allergy to peanut or soya.&#xD;
&#xD;
          5. Non postmenopausal or non surgically sterile woman considered as WOCBP, pregnant or&#xD;
             breastfeeding women.&#xD;
&#xD;
             Prior/Concomitant Therapy&#xD;
&#xD;
          6. Under systemic 5-fluorouracil or any systemic cancer treatment within eight weeks&#xD;
             prior to the study.&#xD;
&#xD;
          7. Under any other topical AK treatments or therapies (e.g., Cryotherapy or Photodynamic&#xD;
             therapy) in the treatment area(s) within eight weeks prior to starting the study.&#xD;
&#xD;
          8. Treated with systemic steroids, immunosuppressants or immunomodulators within four&#xD;
             weeks prior to the study.&#xD;
&#xD;
          9. Under prescription retinoids or topical steroids in the treatment area(s) within four&#xD;
             weeks prior to the study.&#xD;
&#xD;
         10. With known dihydropyrimidinedehydrogénase (DPD) deficiency or under treatment with&#xD;
             brivudine, sorivudine or analogues within 4 weeks prior to starting the study.&#xD;
&#xD;
         11. Treated with glycolic acid products and alpha-hydroxy products in the treatment&#xD;
             area(s) within four weeks prior to starting the study.&#xD;
&#xD;
         12. Treated with chemical peeling products in the treatment area(s) within eight weeks&#xD;
             prior to starting the study.&#xD;
&#xD;
             Prior/Concurrent Clinical Study Experience&#xD;
&#xD;
         13. Is participating in another clinical trial&#xD;
&#xD;
         14. Has participated in another clinical trial within the last 30 days, has received&#xD;
             treatment with known remnant effects or undergone investigation liable to interfere&#xD;
             with the present clinical trial Other Exclusions&#xD;
&#xD;
         15. Is a family member of the Investigator or any associate, colleague, and employee&#xD;
             assisting in the conduct of the study (secretary, nurse, technician,…)&#xD;
&#xD;
         16. Is in a position likely to represent a conflict of interest&#xD;
&#xD;
         17. Has forfeited his / her freedom by administrative or legal award or is under&#xD;
             guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eggert STOCKFLETH, Pr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kath. Klinikum Bochum St. Josef-Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Fabre Médicament</last_name>
    <phone>00 33 5 34 50 60 00</phone>
    <email>contact_essais_cliniques@pierre-fabre.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Private practice Maire</name>
      <address>
        <city>Arras</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cyril MAIRE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Nantes Hôtel-Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brigitte DRENO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Pau</name>
      <address>
        <city>Pau</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas JOUARY</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ewa WIERZBICKA-HAINAUT</last_name>
      <phone_ext>14 007</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU St Etienne Hopital Nord</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Luc PERROT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kath. Klinikum Bochum St. Josef-Hospital</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eggert STOCKFLETH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Private Practice Kurzen</name>
      <address>
        <city>Freising</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hjalmar KURZEN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermatologikum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter WEISENSEEL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Private practice Quist</name>
      <address>
        <city>Mainz-Bretzenheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sven Roy QUIST</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CentroDerm Clinic</name>
      <address>
        <city>Witten</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas DIRSCHKA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uni Clinic Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Piergiacomo CALZAVARA PINTON</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uni Clinic Catania</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MICALI Giuseppe</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uni Clinic L'Aquila</name>
      <address>
        <city>Coppito</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Concetta FARGNOLI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aurora PARODI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Messina</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco BORGIA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uni Clinic Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesca Farnetani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NAPLES VANVITELLI UNIVERSITI (Federico II Hospital)</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe ARGENZIANO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Unità Sanitaria Locale - IRCCS</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherina LONGO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catholic University Fondazione Policlinico Universitario A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ketty PERIS</last_name>
      <phone>Rome</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sapienza University of Rome - Polo Pontino</name>
      <address>
        <city>Terracina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Concetta POTENZA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermatological clinic Almagro</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manuel ALMAGRO SANCHEZ</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre medic Congres</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio MACAYA PASCUAL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Alfredo Espinosa</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne BURRATIA BORQUES</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eva BALBIN CARRERO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología,</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos SERRA-GUILLEN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Marina Baixa</name>
      <address>
        <city>Villajoyosa</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria PEREZ CRESPO</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

